| Abstract |
Objective To analyze the effect and cognitive function of patients undergoing radical mastectomy for breast cancer after treatment with dexmedetomidine. Methods A total of 115 patients who underwent radical mastectomy were enrolled in this study. The anesthesia method was the same in the two groups. 57 patients in the control group were given intravenous saline before anesthesia induction, and 58 patients in the observation group were anesthetized. Intravenous infusion of dexmedetomidine before induction, comparing serum cortisol (Cor), dopamine (DA), norepinephrine (NE), hemodynamics, autonomic balance, cognition after treatment Function and incidence of postoperative adverse events. Results At 1 h after operation, the levels of HF and LF/HF in the observation group were lower than those in the control group. At 6 h after operation, the levels of DA, NE, Cor, HR and SP in the observation group were lower than those in the control group, and the MAP level was higher than that in the control group. The levels of DA, NE, Cor and HR in the observation group were lower than those in the control group, and the MAP level was higher than that in the control group. At 72 hours after operation, the NE level in the observation group was lower than that in the control group; the MMSE score in the observation group was higher than that in the control at 24, 72, and 7 days after operation. The incidence of adverse events was lower in the group than in the control group (P<0.05). Conclusion Dexmedetomidine can effectively inhibit central sympathetic nerve activity, maintain autonomic balance, reduce hemodynamic fluctuations and stress response, promote cognitive function recovery in patients undergoing radical mastectomy, and reduce the incidence of adverse events.
|